Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Adrenergic Agonists: Therapeutic Uses

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.

The Journal of clinical endocrinology and metabolism·2026

Same author

Reassuring long-term data on efficacy and safety of pegvisomant monotherapy in a large series of patients with acromegaly.

Pituitary·2026

Same author

Impact of Osilodrostat on Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials.

Clinical endocrinology·2026

Same author

Differential expression of POMC-processing genes in corticotroph tumors.

Endocrine oncology (Bristol, England)·2026

Same author

Consensus on acromegaly complications: an update.

Pituitary·2026

Same author

Adenoma receptors and histologic characteristics determining management outcomes.

The Journal of clinical endocrinology and metabolism·2026

Search research articles

Related Experiment Video

Updated: Nov 21, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Novel therapies for acromegaly.

Bernardo Maia¹, Leandro Kasuki^1,2,3, Mônica R Gadelha^1,2,4

¹Neuroendocrinology Research Center/Endocrinology Division - Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Endocrine Connections

|January 12, 2021

Summary

Novel therapies are needed for acromegaly, a systemic disease impacting morbidity and mortality. This review summarizes emerging treatments and new drug formulations for patients with persistent disease activity.

Keywords:

acromegaly medical treatment novel treatments oral octreotide somatostatin receptor ligands

More Related Videos

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Nov 21, 2025

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Author Spotlight: Investigating the Mechanism of Action of Acupotomy in Treating Knee Osteoarthritis

Published on: October 20, 2023

Area of Science:

Endocrinology
Internal Medicine
Pharmacology

Background:

Acromegaly is a systemic endocrine disorder linked to increased illness and death.
Effective management of acromegaly can prevent or postpone associated comorbidities.
Current treatments include surgery, medication, and radiotherapy, but some patients remain symptomatic.

Purpose of the Study:

To review novel therapeutic strategies for acromegaly.
To discuss new drug formulations and agents under investigation.
To address the unmet need for effective treatments in refractory acromegaly cases.

Main Methods:

Literature review of recent advancements in acromegaly treatment.
Analysis of ongoing clinical trials and drug development pipelines.
Synthesis of information on novel therapeutic approaches.

Main Results:

Several new drug formulations are being developed to improve efficacy and delivery.
Novel therapeutic agents targeting different pathways of acromegaly are under investigation.
Research indicates potential for improved disease control in patients resistant to current therapies.

Conclusions:

Despite existing treatments, a significant need for novel therapies in acromegaly persists.
Emerging treatments, including new drug formulations and agents, show promise for managing persistent acromegaly.
Continued research is crucial for developing more effective acromegaly treatments.